Absci (ABSI) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Strategic Partnerships and Collaborations

• Entered a $20 million strategic partnership with AMD, including an equity investment, to scale compute, improve price performance, and accelerate AI-driven drug discovery.

• Collaborated with leading industry partners such as AstraZeneca, Almirall, Caltech, the Bill and Melinda Gates Foundation, Merck, MSKCC, Twist Bioscience, Invetx, and Owkin to address challenging targets and expand partnered programs.

• Achieved 2024 partnership guidance with four new partners and over 25 partnered programs.

• Data and compute collaborations with AMD, Oracle, and NVIDIA enhance model performance and efficiency.

• Guiding to announce a new large pharma partnership this year, expected to bring substantial non-dilutive capital.

AI Platform and Technology Advancements

• Launched latest de novo antibody design models, enabling targeting of previously undruggable targets such as HIV Caldera and trastuzumab-resistant HER2 cell lines.

• Proprietary high-throughput data generation and 77,000+ ft² lab support rapid AI model training and validation.

• AMD MI300X chips enable unmatched training resolution and accelerated throughput, allowing design of 12,000+ antibodies in under a week.

• AI lead optimization platform enables co-optimization of antibody attributes, including pH sensitivity and developability.

• Continuous 6-week 'lab in a loop' cycles improve AI models, validated in wet lab.

Pipeline and Clinical Progress

• ABS-101 (anti-TL1A antibody) entering clinic in 1H 2025, with Phase 1 interim data expected 2H 2025.

• ABS-201 (PRLR antibody for androgenic alopecia) initiated IND-enabling activities, aiming to be first in U.S. market, with Phase 1 trial initiation and rapid proof-of-concept opportunity expected in 1H 2026.

• ABS-201 demonstrates superior efficacy to minoxidil in preclinical models and long-lasting hair regrowth in primates.

• ABS-301 and ABS-501: lead and candidate identification for novel programs designed using AI, with ABS-301 targeting immuno-oncology and ABS-501 focused on HER2.

• ABS-201 targets a $14B+ market with significant unmet need and potential for expansion.